The acquisition is expected to enable Myriad to more effecti...
The acquisition is expected to enable Myriad to more effectively scale and grow its tumor profiling offerings to complement its oncology portfolio of hereditary cancer and companion diagnostic testing options.
Press Release: Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory From Intermountain Precision Genomics
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3194Followers
0Following
7962Visitors
Follow